Latest Insider Transactions at Theseus Pharmaceuticals, Inc. (THRX)
This section provides a real-time view of insider transactions for Theseus Pharmaceuticals, Inc. (THRX). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Theseus Pharmaceuticals, Inc. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Theseus Pharmaceuticals, Inc.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 14
2024
|
Bradford D. Dahms President and CFO |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
8,150
-100.0%
|
-
|
|
Feb 14
2024
|
Iain D. Dukes Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
388,324
-100.0%
|
-
|
|
Feb 14
2024
|
Carl L Gordon Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
17,713,600
-100.0%
|
-
|
|
Feb 14
2024
|
Donald J Hayden Jr Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Direct |
10,000
-100.0%
|
-
|
|
Feb 14
2024
|
Orbimed Advisors LLC Director |
SELL
Disposition due to a tender of shares in a change of control transaction
|
Indirect |
17,713,600
-100.0%
|
-
|
|
Nov 06
2023
|
William Shakespeare Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
251,084
+28.2%
|
$0
$0.32 P/Share
|
|
Jul 17
2023
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
479,932
+10.39%
|
$1,439,796
$3.05 P/Share
|
|
Jul 17
2023
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
479,932
+10.39%
|
$1,439,796
$3.05 P/Share
|
|
Jul 17
2023
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
700,000
+11.3%
|
$1,400,000
$2.97 P/Share
|
|
Dec 30
2022
|
Donald J Hayden Jr Director |
BUY
Open market or private purchase
|
Direct |
9,900
+49.75%
|
$49,500
$5.0 P/Share
|
|
Dec 29
2022
|
Foresite Capital Management V, LLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
500,000
+11.83%
|
$2,500,000
$5.0 P/Share
|
|
Dec 29
2022
|
Donald J Hayden Jr Director |
BUY
Open market or private purchase
|
Direct |
100
+50.0%
|
$500
$5.0 P/Share
|
|
Nov 30
2022
|
Bradford D. Dahms President and CFO |
BUY
Open market or private purchase
|
Direct |
1,502
+19.65%
|
$9,012
$6.66 P/Share
|
|
Nov 11
2022
|
Timothy P Clackson President and CEO |
BUY
Open market or private purchase
|
Direct |
2,500
+0.71%
|
$15,000
$6.8 P/Share
|
|
Nov 07
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
192,000
+1.13%
|
$960,000
$5.21 P/Share
|
|
Nov 07
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
192,000
+1.13%
|
$960,000
$5.21 P/Share
|
|
Jan 21
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
111,896
+0.67%
|
$1,007,064
$9.97 P/Share
|
|
Jan 21
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
111,896
+0.67%
|
$1,007,064
$9.97 P/Share
|
|
Jan 20
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
35,000
+0.21%
|
$315,000
$9.95 P/Share
|
|
Jan 20
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
35,000
+0.21%
|
$315,000
$9.95 P/Share
|
|
Jan 19
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
11,521
+0.07%
|
$103,689
$9.97 P/Share
|
|
Jan 19
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
11,521
+0.07%
|
$103,689
$9.97 P/Share
|
|
Jan 13
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
17,320
+0.11%
|
$155,880
$9.43 P/Share
|
|
Jan 13
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
17,320
+0.11%
|
$155,880
$9.43 P/Share
|
|
Jan 12
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
18,897
+0.12%
|
$188,970
$10.06 P/Share
|
|
Jan 12
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
18,897
+0.12%
|
$188,970
$10.06 P/Share
|
|
Jan 11
2022
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
8,500
+0.03%
|
$85,000
$10.24 P/Share
|
|
Jan 11
2022
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
8,500
+0.03%
|
$85,000
$10.24 P/Share
|
|
Dec 21
2021
|
Bradford D. Dahms President and CFO |
BUY
Open market or private purchase
|
Direct |
1,970
+50.0%
|
$19,700
$10.15 P/Share
|
|
Dec 21
2021
|
Timothy P Clackson President and CEO |
BUY
Open market or private purchase
|
Direct |
2,600
+0.74%
|
$23,400
$9.76 P/Share
|
|
Oct 12
2021
|
Takeda Pharmaceutical CO LTD > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
1,615,427
+50.0%
|
-
|
|
Oct 12
2021
|
Omega Fund Vi, L.P. |
BUY
Open market or private purchase
|
Direct |
187,500
+20.86%
|
$3,000,000
$16.0 P/Share
|
|
Oct 12
2021
|
Omega Fund Vi, L.P. |
BUY
Conversion of derivative security
|
Direct |
523,979
+50.0%
|
-
|
|
Oct 12
2021
|
William Shakespeare Officer |
BUY
Open market or private purchase
|
Direct |
625
+0.16%
|
$10,000
$16.0 P/Share
|
|
Oct 12
2021
|
Carl L Gordon Director |
BUY
Open market or private purchase
|
Indirect |
625,000
+7.23%
|
$10,000,000
$16.0 P/Share
|
|
Oct 12
2021
|
Carl L Gordon Director |
BUY
Conversion of derivative security
|
Indirect |
16,213,668
+50.0%
|
-
|
|
Oct 12
2021
|
Orbimed Advisors LLC Director |
BUY
Open market or private purchase
|
Indirect |
625,000
+7.23%
|
$10,000,000
$16.0 P/Share
|
|
Oct 12
2021
|
Orbimed Advisors LLC Director |
BUY
Conversion of derivative security
|
Indirect |
16,213,668
+50.0%
|
-
|
|
Oct 12
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
250,000
+29.44%
|
$4,000,000
$16.0 P/Share
|
|
Oct 12
2021
|
Rock Springs Capital Management LP > 10% Shareholder |
BUY
Conversion of derivative security
|
Indirect |
436,649
+50.0%
|
-
|